All Stories

  1. Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review
  2. Low oxygen levels decrease adaptive immune responses and ameliorate experimental asthma in mice
  3. Impact of Smoking Behavior on Survival Following Allogeneic Hematopoietic Stem Cell Transplantation – Smoking Cessation Matters
  4. The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease
  5. TMEM16A Potentiation: Possible Drawbacks
  6. Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria – Results from the CLARA Project
  7. Disconnect between Fibrotic Response and Right Ventricular Dysfunction
  8. Should patients with pulmonary hypertension fly and climb?
  9. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?
  10. Are anticoagulants still indicated in pulmonary arterial hypertension?
  11. Pulmonary hypertension in hypersensitivity pneumonitis.
  12. Right ventricular tissue doppler echocardiography in pulmonary hypertension
  13. Right ventricular fibrosis and dysfunction: Actual concepts and common misconceptions
  14. Identification of rare sequence variation underlying heritable pulmonary arterial hypertension
  15. Resident cell lineages are preserved in pulmonary vascular remodeling
  16. Pulmonary capillary recruitment in exercise and pulmonary hypertension
  17. Mild Elevation of Pulmonary Arterial Pressure as a Predictor of Mortality
  18. Network Analysis to Risk Stratify Patients With Exercise IntoleranceNovelty and Significance
  19. The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension
  20. No erythropoietin-induced growth is observed in non-small cell lung cancer cells
  21. MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas
  22. An official European Respiratory Society statement: pulmonary haemodynamics during exercise
  23. Importance of kynurenine in pulmonary hypertension
  24. Understanding exercise hemodynamics
  25. TR3 is involved in hypoxia-induced apoptosis resistance in lung cancer cells downstream of HIF-1α
  26. Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study
  27. Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox
  28. The safety and pharmacokinetics of rapid iloprost aerosol delivery via the BREELIB nebulizer in pulmonary arterial hypertension
  29. Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia
  30. Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis
  31. Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension
  32. Automated integer programming based separation of arteries and veins from thoracic CT images
  33. ESC-Leitlinie 2015: Diagnostik und Therapie der pulmonalen Hypertonie
  34. Pulmonale Hypertonie: Kölner Konsensus-Konferenz 2016
  35. Pulmonale Hypertonie bei Lungenkrankheiten: Empfehlungen der Kölner Konsensus-Konferenz 2016
  36. Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different?
  37. Why We Should Care about the Mysteries of Pulmonary Hypertension
  38. Does exercise pulmonary hypertension exist?
  39. Docosahexaenoic acid causes rapid pulmonary arterial relaxationviaKCa channel-mediated hyperpolarisation in pulmonary hypertension
  40. Counter-clockwise vortical blood flow in the main pulmonary artery in a patient with patent ductus arteriosus with pulmonary arterial hypertension: a cardiac magnetic resonance imaging case report
  41. Amitriptyline and carbamazepine utilize voltage-gated ion channel suppression to impair excitability of sensory dorsal horn neurons in thin tissue slice: An in vitro study
  42. Functional and molecular factors associated with TAPSE in hypoxic pulmonary hypertension
  43. TASK-1 Regulates Apoptosis and Proliferation in a Subset of Non-Small Cell Lung Cancers
  44. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
  45. Forschung in Österreich – das Ludwig Boltzmann Institut für Lungengefäßforschung
  46. Survival in patients with borderline pulmonary arterial pressure
  47. Prognostic relevance of differential blood count in pulmonary arterial hypertension
  48. Native myocardial T1 mapping in pulmonary hypertension: correlations with cardiac function and hemodynamics
  49. Circulating endothelial progenitor cells are associated with PAH but they are heterogeneous
  50. Pulmonary arterial pressure in patients with myelodysplastic syndromes
  51. Pulmonal (arterielle) Hypertonie
  52. Pulmonalembolie und direkte orale Antikoagulantien
  53. Letter by Olschewski et al Regarding Article, “Upregulation of K 2P 3.1 K + Current Causes Action Potential Shortening in Patients With Chronic Atrial Fibrillation”
  54. Proposed new definition of exercise pulmonary hypertension decreases false-positive cases
  55. Pulmonale Hypertonie
  56. Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension – Insights From the IBUKI and AIR Studies –
  57. Selexipag for the Treatment of Pulmonary Arterial Hypertension
  58. Clinical Manifestations of Respiratory Bronchiolitis as an Incidental Finding in Surgical Lung Biopsies: A Retrospective Analysis of a Large Austrian Registry
  59. ESC-Leitlinien 2015 zur pulmonalen Hypertonie
  60. Sleep Related Breathing Disorders and Inflammation — The Missing Link? A Cohort Study Evaluating the Interaction of Inflammation and Sleep Related Breathing Disorders and Effects of Treatment
  61. Cardiopulmonary comorbidities are associated with hemodynamics in pulmonary arterial hypertension
  62. The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines
  63. Pressure Overload Creates Right Ventricular Diastolic Dysfunction in a Mouse Model: Assessment by Echocardiography
  64. Borderline pulmonary pressures in scleroderma - a ‘pre-pulmonary arterial hypertension’ condition?
  65. Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients
  66. Impact of cardiopulmonary comorbidities on pulmonary hemodynamics
  67. Blood Flow Vortices along the Main Pulmonary Artery Measured with MR Imaging for Diagnosis of Pulmonary Hypertension
  68. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization
  69. Imatinib for Pulmonary Arterial Hypertension - Wonder Drug or Killer Drug?
  70. Allgemeine Therapie der pulmonal arteriellen Hypertonie
  71. Einsatz von Imatinib bei Patienten mit Pulmonal Arterieller Hypertonie
  72. Moderne bildgebende Verfahren im Management der pulmonalen Hypertonie
  73. Gezielte Therapie der pulmonal arteriellen Hypertonie (PAH)
  74. Ion channels and transporters as therapeutic targets in the pulmonary circulation
  75. Characterization of Patients With Borderline Pulmonary Arterial Pressure
  76. Reply: Reading of Pulmonary Artery Pressure Tracings: The Best Compromise of Accuracy and Clinical Pertinence
  77. Diagnostik der pulmonalen Hypertonie – Neues nach dem 5. Weltkongress
  78. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics
  79. Gluconeogenesis in cancer: Door wide open
  80. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients
  81. Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries
  82. Distinct Differences in Gene Expression Patterns in Pulmonary Arteries of Patients with Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis with Pulmonary Hypertension
  83. READING PULMONARY VASCULAR PRESSURE TRACINGS How to handle the problems of zero leveling and respiratory swings
  84. Complete resolution of idiopathic pulmonary arterial hypertension following chemotherapy
  85. Kurzatmiger Patient — nicht immer ist er nur untrainiert
  86. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer
  87. Meprinβ, a novel mediator of vascular remodelling underlying pulmonary hypertension
  88. Quantification of Tortuosity and Fractal Dimension of the Lung Vessels in Pulmonary Hypertension Patients
  89. Hypoxia increases membrane metallo-endopeptidase expression in a novel lung cancer ex vivo model – role of tumor stroma cells
  90. Changes in Right Ventricular Function Measured by Cardiac Magnetic Resonance Imaging in Patients Receiving Pulmonary Arterial Hypertension–Targeted Therapy
  91. Evaluation of Elevated Mean Pulmonary Arterial Pressure Based on Magnetic Resonance 4D Velocity Mapping: Comparison of Visualization Techniques
  92. Was ist pulmonale Hypertonie?
  93. Non-invasive determination of pulmonary hypertension with dynamic contrast-enhanced computed tomography: a pilot study
  94. Updated Clinical Classification of Pulmonary Hypertension
  95. Pulmonary arterial hypertension
  96. Assessment and Prognostic Relevance of Right Ventricular Contractile Reserve in Patients With Severe Pulmonary Hypertension
  97. Docosahexaenoic acid (DHA)-induced heme oxygenase-1 attenuates cytotoxic effects of DHA in vascular smooth muscle cells
  98. PL-7 Positive Antisynthetase Syndrome and Pulmonary Hypertension
  99. Determination of cardiac output with dynamic contrast-enhanced computed tomography
  100. Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
  101. Riociguat for the Treatment of Pulmonary Arterial Hypertension
  102. Pulmonary Hypertension
  103. Biomarkers in Pulmonary Hypertension
  104. A 57-Year-Old Woman With Obesity, Respiratory Insufficiency, and Slowed Mental State
  105. Die frühe Diagnose und Therapie der pulmonalen Hypertonie - Aspekte einer Vision
  106. Zero reference level for right heart catheterisation
  107. Double-Stranded RNA Attenuates the Barrier Function of Human Pulmonary Artery Endothelial Cells
  108. Stellungnahme der Österreichischen Röntgengesellschaft und der Österreichischen Gesellschaft für Pneumologie
  109. Loss of ABCG2 leads to right ventricular diastolic dysfunction in pulmonary hypertension
  110. Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension
  111. Prostacyclins
  112. Exercise in Pulmonary Hypertension
  113. HbA1c in pulmonary arterial hypertension: A marker of prognostic relevance?
  114. Pulmonale Hypertonie
  115. Angiostatic Factors in the Pulmonary Endarterectomy Material from Chronic Thromboembolic Pulmonary Hypertension Patients Cause Endothelial Dysfunction
  116. Docosahexaenoic acid-induced unfolded protein response, cell cycle arrest, and apoptosis in vascular smooth muscle cells are triggered by Ca2+-dependent induction of oxidative stress
  117. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries
  118. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure
  119. Peroxisome Proliferator–Activated Receptor–β/δ, the Acute Signaling Factor in Prostacyclin-Induced Pulmonary Vasodilation
  120. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The TReprostinil sodium Inhalation Used in the Management of Pulmonary arterial Hypertension (TRIUMPH) study open-label extension
  121. Treatment of pulmonary arterial hypertension (PAH): Updated Recommendations of the Cologne Consensus Conference 2011
  122. Rechtsherzkatheter-Untersuchung bei pulmonaler Hypertonie
  123. Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations
  124. Regulation der Kaliumkanäle in humanen pulmonal-arteriellen glatten Muskelzellen
  125. Pulmonary vascular resistances during exercise in normal subjects: a systematic review
  126. Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells
  127. Diagnosis of CTEPH versus IPAH using capillary to end-tidal carbon dioxide gradients
  128. Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension
  129. Prostacyclin and Prostaglandins
  130. Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy
  131. Therapie der pulmonal arteriellen Hypertonie (PAH)
  132. Assessment of Pulmonary Arterial Pressure During Exercise in Collagen Vascular Disease
  133. Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension
  134. Long-term therapy with inhaled iloprost in patients with pulmonary hypertension
  135. Intimal Sarcoma of the Pulmonary Valve
  136. Portopulmonary hypertension: short review
  137. The effect of terbutaline on the absorption of pulmonary administered insulin in subjects with asthma
  138. Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma
  139. Long-Term Ambrisentan Therapy for the Treatment of Pulmonary Arterial Hypertension
  140. Noninvasive detection of early pulmonary vascular dysfunction in scleroderma
  141. Endothelin-1 Inhibits Background Two-Pore Domain Channel TASK-1 in Primary Human Pulmonary Artery Smooth Muscle Cells
  142. Bildgebende Verfahren in Diagnostik und Verlaufskontrolle der pulmonalen arteriellen Hypertonie
  143. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy
  144. Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
  145. Diagnosis and Assessment of Pulmonary Arterial Hypertension
  146. Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial Hypertension
  147. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review
  148. Inhaled iloprost for the treatment of pulmonary hypertension
  149. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension
  150. Ambrisentan Therapy in Patients With Pulmonary Arterial Hypertension Who Discontinued Bosentan or Sitaxsentan Due to Liver Function Test Abnormalities
  151. A 55-year-old craftsman with dyspnea and clubbing: a case report
  152. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension
  153. Dana Point: Was ist neu in der Diagnostik der Pulmonalen Hypertonie?
  154. Magnetic Resonance–Derived 3-Dimensional Blood Flow Patterns in the Main Pulmonary Artery as a Marker of Pulmonary Hypertension and a Measure of Elevated Mean Pulmonary Arterial Pressure
  155. Oral and IntestinalCandidaColonization in Patients Undergoing Hematopoietic Stem‐Cell Transplantation
  156. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension
  157. Prostacyclin therapies for the treatment of pulmonary arterial hypertension
  158. The Emerging Role of Magnetic Resonance Imaging in the Diagnosis and Management of Pulmonary Hypertension
  159. Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function
  160. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension
  161. Pulmonary Histoplasmosis in Three Austrian Travelers After a Journey to Mexico
  162. Highlights der Pulmonalen Hypertonie-Literatur
  163. Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes
  164. Delayed Processing of Blood Samples Influences Time to Positivity of Blood Cultures and Results of Gram Stain-Acridine Orange Leukocyte Cytospin Test
  165. Aspergillus oryzae Peritonitis in CAPD: Case Report and Review of the Literature
  166. Diagnostik und Therapie der chronischen pulmonalen Hypertonie
  167. Effect of Inhaled Iloprost during Off-Medication Time in Patients with Pulmonary Arterial Hypertension
  168. Diagnostik und Therapie der chronischen pulmonalen Hypertonie
  169. Derzeitige Empfehlungen zur Diagnostik und Therapie der pulmonalen Hypertonie
  170. Therapie der pulmonalarteriellen Hypertonie: Prostazyklin-Analoga
  171. Exercise and Respiratory Training Improve Exercise Capacity and Quality of Life in Patients With Severe Chronic Pulmonary Hypertension
  172. Favorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension
  173. Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to Bosentan in Pulmonary Arterial Hypertension
  174. Stellenwert der Lyse bei akuter Lungenembolie
  175. Sildenafil treatment for portopulmonary hypertension
  176. Impact of TASK-1 in Human Pulmonary Artery Smooth Muscle Cells
  177. Pulmonale Hypertonie: Die Zukunft hat begonnen
  178. Mutations of the TGF-β type II receptorBMPR2 in pulmonary arterial hypertension
  179. Inhaled Treprostinil for Treatment of Chronic Pulmonary Arterial Hypertension
  180. Diagnosis and treatment of pulmonary hypertonia
  181. Sildenafil Improves Dynamic Vascular Function in the Brain: Studies in Patients with Pulmonary Hypertension
  182. Enhanced Hypoxic Pulmonary Vasoconstriction in Families of Adults or Children With Idiopathic Pulmonary Arterial Hypertension
  183. Serotonin Transporter Gene Polymorphism in a Cohort of German Patients With Idiopathic Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
  184. Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents
  185. Ambrisentan Therapy for Pulmonary Arterial Hypertension
  186. Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar
  187. Medikament�se Therapie der pulmonalen Hypertonie
  188. Low frequency of BMPR2 mutations in a German cohort of patients with sporadic idiopathic pulmonary arterial hypertension
  189. Vasodilators in right heart failure - pro
  190. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionA randomized prospective study
  191. Sildenafil Increased Exercise Capacity during Hypoxia at Low Altitudes and at Mount Everest Base Camp
  192. Diagnosis and differential assessment of pulmonary arterial hypertension
  193. Prostanoid therapy for pulmonary arterial hypertension
  194. Prostacyclin and its analogues in the treatment of pulmonary hypertension
  195. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV‐related severe pulmonary hypertension
  196. Reversal of Nocturnal Periodic Breathing in Primary Pulmonary Hypertension After Lung Transplantation
  197. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia
  198. Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension
  199. Zardaverine and aerosolised iloprost in a model of acute respiratoryfailure
  200. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension
  201. Primary pulmonary hypertension may be a heterogeneous disease with a second locus on chromosome 2q31
  202. Sildenafil for Long-Term Treatment of Nonoperable Chronic Thromboembolic Pulmonary Hypertension
  203. Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost
  204. Pulmonaler Hochdruck
  205. Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension
  206. Sildenafil zur Therapie der schweren pulmonalen Hypertonie und des beginnenden Rechtsherzversagens
  207. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial
  208. Inhaled Iloprost for Severe Pulmonary Hypertension
  209. Peripheral airway obstruction in primary pulmonary hypertension
  210. Aerosolized Vasodilators in Pulmonary Hypertension
  211. Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension
  212. Lung cGMP release subsequent to NO inhalation in pulmonary hypertension: respondersversusnonresponders
  213. Nocturnal periodic breathing in primary pulmonary hypertension
  214. Outcome after Cardiopulmonary Resuscitation in Patients with Pulmonary Arterial Hypertension
  215. Cellular pathophysiology and therapy of pulmonary hypertension
  216. Recommendations for the Choice of Inhalatory Systems for Drug Prescription
  217. Physiologic basis for the treatment of pulmonary hypertension
  218. Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension
  219. Basic Electrical Properties ofIn situEndothelial Cells of Small Pulmonary Arteries during Postnatal Development
  220. Obstructive Sleep Apnoea and Cardiovascular Diseases - Hypothesis of Pathophysiological Interlinks
  221. Does the tuberous sclerosis complex include clivus chordoma? A case report
  222. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
  223. Decreased plasma levels of nitric oxide derivatives in obstructive sleep apnoea: response to CPAP therapy
  224. Diagnostik der akuten Lungenembolie - Empfehlungen der Deutsche Gesellschaft für Pneumologie -
  225. Prävalenz von Schlaganfall und transitorischer ischämischer Attacke (TIA) bei obstruktiver Schlaf-Apnoe: eine retrospektive Erhebung an 187 konsekutiven Patienten1
  226. Abnormal Pulmonary Artery Pressure Response in Asymptomatic Carriers of Primary Pulmonary Hypertension Gene
  227. Enhanced Release of Superoxide from Polymorphonuclear Neutrophils in Obstructive Sleep Apnea
  228. Inhalative Strategien zur Verbesserung der pulmonalen Hämodynamik und des Gasaustausches bei Sepsis und schwerer pulmonaler Hypertonie
  229. Behandlung der Pulmonal Arteriellen Hypertonie
  230. Screen–printed enzyme sensors for l-lysine determination
  231. Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
  232. Inhaliertes Prostazyklin und Iloprost bei schwerer sekundärer pulmonaler Hypertonie durch Lungenfibrose1
  233. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
  234. Severe Microcirculatory Abnormalities Elicited byE. coliHemolysin in the Rabbit Ileum Mucosa
  235. Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis
  236. Physiologie und Pathophysiologie der pulmonalen Zirkulation
  237. Vasotrope Therapie und Beatmung bei pulmonaler Hypertonie
  238. Effect of bupivacaine on ATP-dependent potassium channels in rat cardiomyocytes
  239. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost
  240. Abnormalities of Gastric Mucosal Oxygenation in Septic Shock
  241. NO und alternative inhalative Therapieansätze bei pulmonaler Hypertonie
  242. Advantage of buffered solutions or automated capnometry in air-filled balloons for use in gastric tonometry
  243. Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension
  244. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.
  245. ATP-Dependent Potassium Channel in Rat Cardiomyocytes Is Blocked by Lidocaine
  246. Temperature effects on ventilatory rate, heart rate, and preferred pedal rate during cycle ergometry
  247. Cardiac responses to the Valsalva manoeuvre in different body positions
  248. Thermoregulatory, cardiovascular, and muscular factors related to exercise after precooling
  249. Body temperature related factors diminishing the drive to exercise
  250. Pulmonary Hypertension